Harvard Pilgrim Health Care Home
  Learn more.
  Sign up for HPHConnect.
Medical Management
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Office Support
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

January 2015

Quantity Limits on Extended-Release Morphine Medications 

Effective March 15, 2015, Harvard Pilgrim will be instituting the following quantity limits on extended-release morphine products to ensure the safe and appropriate use of these products.

  • Avinza, Kadian, and generic morphine sulfate ER capsules: Maximum 2 units per day.
  • MS Contin and generic morphine sulfate ER tablets: Maximum 3 units per day.

These limits will not apply for members who are currently taking these medications in addition to cancer drug treatment. On January 15th, Harvard Pilgrim will notify any members who have filled prescriptions within the last 3 months for these medications in quantities that exceed the daily limit of this change.

These quantity limits apply to our Premium and Medicare Advantage formularies, as well as for the extended-release morphine products that are covered on our Value formulary. (Brand name extended-release morphine products that have generic equivalents are not covered in the Value formulary.)

For further information, please refer to Harvard Pilgrim’s Pharmacy website, which includes the Premium and Value formularies as well as a list of medications with quantity limitations or quantity-based copayments.

Email this article to a colleague   

Network Matters Archives

Download printer-friendly version


Reminder: New Version of CAQH Coming in February

Health Plans Acquires TrestleTree for Wellness Management


Appropriate Coding for Monovisc

Quantity Limits on Extended-Release Morphine Medications

Coverage for Diagnostic Ultrasound Exams

Payment policy updates: Radiology

Diagnosis Coding for HEDIS and Risk Adjustment

Identifying and Treating Seasonal Affective Disorder

P&T Committee Updates

Specialty Pharmacy Program Updates


2015 Fee Schedule Updates

HPHConnect Account Management for Inactive Users

Reminder: Ensure That Claims Contain Valid Codes


Eric H. Schultz,
President and Chief Executive Officer

Richard Weisblatt PhD,
Senior Vice President, Provider Network

Annmarie Dadoly,

Joseph O'Riordan,
Contributing Writer

Kristin Edmonston,
Production Coordinator